Published in Cell Stem Cell on February 07, 2008
Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell (2008) 6.26
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal (2011) 3.31
Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther (2009) 3.20
Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell (2012) 2.87
Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A (2008) 2.70
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med (2013) 2.60
Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol (2011) 2.38
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther (2010) 2.29
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med (2010) 2.22
Immunobiology of mesenchymal stem cells. Cell Death Differ (2013) 2.18
Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol (2010) 2.12
Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin (2013) 2.10
The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A (2009) 2.07
Stem cell paracrine actions and tissue regeneration. Regen Med (2010) 1.99
Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol (2011) 1.97
CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97
Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther (2010) 1.95
How mesenchymal stem cells interact with tissue immune responses. Trends Immunol (2012) 1.92
IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One (2010) 1.92
Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol (2009) 1.88
Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med (2011) 1.72
Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One (2010) 1.64
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A (2011) 1.58
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation (2013) 1.53
mTOR inhibition rescues osteopenia in mice with systemic sclerosis. J Exp Med (2014) 1.52
Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Stem Cell Res Ther (2012) 1.48
Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med (2009) 1.42
Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol (2010) 1.41
Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ (2012) 1.41
Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells. Physiol Rev (2011) 1.40
Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev (2011) 1.37
Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J (2014) 1.37
Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-α. Nat Protoc (2012) 1.34
Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem (2012) 1.33
Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med (2013) 1.33
Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med (2012) 1.32
Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol (2012) 1.31
MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int (2013) 1.30
Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease. Stem Cells (2011) 1.29
Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells (2014) 1.29
Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther (2010) 1.28
Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther (2011) 1.28
Mesenchymal stem cells: Molecular characteristics and clinical applications. World J Stem Cells (2010) 1.27
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
Cell therapy of congenital corneal diseases with umbilical mesenchymal stem cells: lumican null mice. PLoS One (2010) 1.26
Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther (2013) 1.26
Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther (2009) 1.24
Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM R (2009) 1.22
Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol (2010) 1.22
Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One (2009) 1.21
Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood (2012) 1.20
Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide. PLoS One (2011) 1.20
Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther (2012) 1.19
The stem cell secretome and its role in brain repair. Biochimie (2013) 1.19
Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells. Stem Cells Transl Med (2011) 1.19
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Clinical applications of mesenchymal stem cells. Korean J Intern Med (2013) 1.18
The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol (2011) 1.16
Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells(). Cell Med (2012) 1.14
Regulation of T cell priming by lymphoid stroma. PLoS One (2011) 1.14
Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells (2014) 1.14
Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One (2012) 1.13
Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab (2013) 1.13
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 1.13
CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One (2013) 1.13
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. Cell Death Dis (2013) 1.12
Conditionally immortalized mouse embryonic fibroblasts retain proliferative activity without compromising multipotent differentiation potential. PLoS One (2012) 1.11
Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev (2014) 1.10
Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One (2012) 1.10
Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res (2014) 1.10
High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol (2009) 1.10
Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells (2012) 1.09
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
How do mesenchymal stromal cells suppress T cells? Cell Stem Cell (2008) 1.08
Transcriptomics comparison between porcine adipose and bone marrow mesenchymal stem cells during in vitro osteogenic and adipogenic differentiation. PLoS One (2012) 1.08
How stem cells speak with host immune cells in inflammatory brain diseases. Glia (2013) 1.08
Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther (2013) 1.07
IL1β induces mesenchymal stem cells migration and leucocyte chemotaxis through NF-κB. Stem Cell Rev (2012) 1.07
Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology (2012) 1.07
Tailored integrin-extracellular matrix interactions to direct human mesenchymal stem cell differentiation. Stem Cells Dev (2012) 1.06
Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Commun Signal (2012) 1.06
Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells (2013) 1.06
Bone marrow mesenchymal stem cells can differentiate and assume corneal keratocyte phenotype. J Cell Mol Med (2012) 1.06
Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J Dent Res (2012) 1.05
Lymphocyte development requires S-nitrosoglutathione reductase. J Immunol (2010) 1.05
Mouse mandible contains distinctive mesenchymal stem cells. J Dent Res (2010) 1.05
Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM (2014) 1.04
Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation (2012) 1.04
T cells: critical bone regulators in health and disease. Bone (2010) 1.04
Therapy with stem cells in inflammatory bowel disease. World J Gastroenterol (2014) 1.03
Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis (2016) 1.03
Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther (2013) 1.03
Current and future regenerative medicine - principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine. Can Vet J (2009) 1.03
Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Ther (2012) 1.03
Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A (2010) 1.02
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Interleukin-10 and related cytokines and receptors. Annu Rev Immunol (2004) 5.41
How Saccharomyces responds to nutrients. Annu Rev Genet (2008) 3.92
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Use of aldosterone antagonists in heart failure. JAMA (2009) 3.00
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol (2013) 2.90
Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun (2005) 2.83
Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells (2009) 2.71
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med (2012) 2.66
Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol (2009) 2.37
Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci U S A (2013) 2.33
Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation (2010) 2.32
Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity (2006) 2.21
Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation (2010) 2.15
Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol (2010) 2.12
Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation (2008) 2.09
Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica (2007) 2.07
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03
Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. Circ Cardiovasc Qual Outcomes (2010) 2.02
Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest (2006) 2.02
CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94
IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol (2011) 1.94
HIV-testing behavior among young migrant men who have sex with men (MSM) in Beijing, China. AIDS Care (2011) 1.93
How mesenchymal stem cells interact with tissue immune responses. Trends Immunol (2012) 1.92
Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A (2005) 1.91
Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med (2009) 1.89
Clinical applications of mesenchymal stem cells. J Hematol Oncol (2012) 1.86
Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol (2009) 1.81
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest (2009) 1.80
Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. Stroke (2014) 1.76
Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. J Pain Symptom Manage (2012) 1.76
Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int J Radiat Oncol Biol Phys (2009) 1.75
Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med (2011) 1.72
Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun (2006) 1.72
Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J (2004) 1.70
Brain edema after intracerebral hemorrhage in rats: the role of inflammation. Neurol India (2006) 1.69
Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res (2009) 1.68
Reperfusion is a stronger predictor of good clinical outcome than recanalization in ischemic stroke. Radiology (2013) 1.67
Function, attachment and synthesis of lipoic acid in Escherichia coli. Adv Microb Physiol (2005) 1.66
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol (2012) 1.65
Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation (2004) 1.65
Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res (2009) 1.64
Conformational flexibility facilitates self-assembly of complex DNA nanostructures. Proc Natl Acad Sci U S A (2008) 1.60
TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. J Biochem (2011) 1.59
Psychometric evaluation of the Trauma Symptoms Checklist for Children (TSCC) among children affected by HIV/AIDS in China. AIDS Care (2009) 1.59
Escherichia coli and Staphylococcus aureus elicit differential innate immune responses following intramammary infection. Clin Diagn Lab Immunol (2004) 1.58
Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail (2010) 1.57
Bilateral inhibition of gamma-aminobutyric acid type A receptor function within the basolateral amygdala blocked propofol-induced amnesia and activity-regulated cytoskeletal protein expression inhibition in the hippocampus. Anesthesiology (2008) 1.54
HIV/AIDS-related sexual risk behaviors among rural residents in China: potential role of rural-to-urban migration. AIDS Educ Prev (2007) 1.53
Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res (2009) 1.52
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 1.52
Water stress-responsive genes in loblolly pine (Pinus taeda) roots identified by analyses of expressed sequence tag libraries. Tree Physiol (2006) 1.51
The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke (2010) 1.50
Repair of chronic type B dissection with aortic arch involvement using a stented elephant trunk procedure. Ann Thorac Surg (2010) 1.50
Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J Exp Med (2010) 1.50
Second window of preconditioning normalizes palmitate use for oxidation and improves function during low-flow ischaemia. Cardiovasc Res (2011) 1.49
miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol (2009) 1.49
Development of a luciferase-based reporter of transcriptional gene silencing that enables bidirectional mutant screening in Arabidopsis thaliana. Silence (2012) 1.49
sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One (2011) 1.45
Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion. Radiology (2009) 1.43
Ontario radiation oncology residents' needs in the first postgraduate year-residents' perspective survey. Int J Radiat Oncol Biol Phys (2007) 1.43
Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Res Ther (2010) 1.43
Improved wait time intervals for prostate cancer patients in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern. Can Urol Assoc J (2013) 1.42
Multipotency of Flk1CD34 progenitors derived from human fetal bone marrow. J Lab Clin Med (2004) 1.42
CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med (2007) 1.40
Perspectives: on being a visiting scientist. J Lab Clin Med (2002) 1.40
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
MicroRNA hsa-miR-138 inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells through adenovirus EID-1. Stem Cells Dev (2010) 1.39
Quality of care in women with ischemic stroke in the GWTG program. Stroke (2009) 1.39
TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity (2002) 1.39
Genome-wide analysis reveals inositol, not choline, as the major effector of Ino2p-Ino4p and unfolded protein response target gene expression in yeast. J Biol Chem (2004) 1.39
Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity (2011) 1.38
Human DNA ligases I and III, but not ligase IV, are required for microhomology-mediated end joining of DNA double-strand breaks. Nucleic Acids Res (2008) 1.37
Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res (2007) 1.35